Valuation: Artiva Biotherapeutics, Inc.

Market Cap 296M 263M 244M 222M 419M 28.12B 426M 2.93B 1.15B 14.67B 1.11B 1.09B 46.78B P/E 2026 *
-2.34x
P/E 2027 * -2.24x
Enterprise Value 296M 263M 244M 222M 419M 28.12B 426M 2.93B 1.15B 14.67B 1.11B 1.09B 46.78B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
84.9%
Yield 2026 *
-
Yield 2027 * -
1 day-3.22%
1 week-15.49%
Current month-17.63%
1 month-31.80%
3 months-35.12%
6 months-51.57%
Current year+36.71%
1 week 5.82
Extreme 5.82
6.94
1 month 5.82
Extreme 5.82
8.75
Current year 3.62
Extreme 3.62
14.53
1 year 2.96
Extreme 2.96
14.53
3 years 1.47
Extreme 1.47
17.31
5 years 1.47
Extreme 1.47
17.31
10 years 1.47
Extreme 1.47
17.31
Manager TitleAgeSince
Chief Executive Officer 51 2021-01-04
President 63 2026-05-17
Chief Tech/Sci/R&D Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 40 2020-05-31
Director/Board Member 51 2021-01-04
Chairman 67 2020-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Sell

Chief Executive Officer

-23,463 0.0963%
10/5/26 Sell

Chief Technology Officer

-10,340 0.0424%
10/5/26 Sell

Chief Executive Officer

-61,696 0.2532%
Change 5-day change 1-year change 3-year change Capi.($)
-3.47%-15.49%+111.73% - 296M
-6.60%-10.93%+45.08%+60.01% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-1.45%+2.60%+29.60%+34.01% 44.61B
-5.90%-5.90%+259.42%+423.33% 40.57B
-1.28%+4.10%+16.03%+112.14% 42.53B
+6.53%+8.02%+18.98%+54.58% 30.95B
-0.90%-10.91%+34.11%-1.83% 25.44B
-2.85%-9.74%-16.71%-9.75% 22.66B
Average -2.01%+0.28%+51.07%+85.45% 38B
Weighted average by Cap. -2.46%+1.64%+45.75%+89.69%

Financials

2026 *2027 *
Net sales - -
Net income -107M -95.11M -88.15M -80.2M -151M -10.15B -154M -1.06B -415M -5.3B -402M -393M -16.89B -135M -120M -111M -101M -191M -12.84B -194M -1.34B -525M -6.7B -508M -497M -21.36B
Net Debt - -
Projected Income Statement - Annual - Artiva Biotherapeutics, Inc.
Logo Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Employees
115
Date Price Change Volume
26-10-16 US$5.840 -3.63% 509,050
26-10-15 US$6.060 +2.54% 478,246
26-10-14 US$5.910 -6.04% 707,557
26-10-13 US$6.290 -7.09% 526,968
26-10-12 US$6.770 -2.45% 248,580
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Artiva Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.060USD
Average target price
35.80USD
Spread / Average Target
+490.76%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Artiva Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ARTV Stock